Predictive Oncology Acquires Bio-Genetics, Raises $1.5M

Ticker: AGPU · Form: 8-K · Filed: Jul 24, 2025 · CIK: 1446159

Sentiment: mixed

Topics: acquisition, financing, convertible-notes

TL;DR

PRED buys Bio-Genetics, raises $1.5M in notes. Big moves in oncology.

AI Summary

Predictive Oncology Inc. announced on July 23, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of privately held Bio-Genetics, Inc. for an undisclosed amount. This acquisition is expected to close in the third quarter of 2025, subject to customary closing conditions. The company also announced a concurrent private placement of $1.5 million in convertible notes.

Why It Matters

The acquisition of Bio-Genetics could expand Predictive Oncology's capabilities in the oncology space, while the capital raise provides funding for operations and potential future growth.

Risk Assessment

Risk Level: medium — The acquisition is for an undisclosed amount, and the company is raising capital through convertible notes, which can introduce dilution risk.

Key Numbers

Key Players & Entities

FAQ

What is the purchase price for Bio-Genetics, Inc.?

The purchase price for Bio-Genetics, Inc. is not disclosed in this filing.

When is the acquisition of Bio-Genetics expected to close?

The acquisition is expected to close in the third quarter of 2025.

What is the purpose of the $1.5 million in convertible notes?

The convertible notes are intended to provide funding for the company's operations and potential future growth.

What is the filing date of this 8-K report?

This 8-K report was filed on July 24, 2025, reporting events as of July 23, 2025.

What was Predictive Oncology Inc. formerly known as?

Predictive Oncology Inc. was formerly known as Skyline Medical Inc. until August 7, 2013.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 24, 2025 regarding Predictive Oncology Inc. (AGPU).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing